A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

Start Date13 Mar 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06541678

/ CompletedPhase 1

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Itraconazole and Cyclosporine on the Single-Dose Pharmacokinetics of Danuglipron in Healthy Adult Participants

The purpose of this study is to see how single dose of cyclosporine and multiple doses of itraconazole affect the level of the study medicine danuglipron in the blood of healthy adult participants. The information from this study may inform how danuglipron will be used in the future with medicines like cyclosporine and itraconazole.

Start Date23 Dec 2024

Sponsor / Collaborator

Pfizer Inc.

NCT06567327

/ CompletedPhase 1

A Two-Part Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and The Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight or Obesity

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:
* how the study medicine, danuglipron, is taken up into the blood
* if the study medicine, danuglipron, changes how the body processes other study medicines (Atorvastatin and Rosuvastatin)
* about the safety and tolerability of danuglipron
The study will take place in 4 Cohorts (groups). The total number of weeks of the study is about 23 (about 6 months) for Cohort 1 and 22 weeks (about 5.5 months) for Cohort 2, 21 weeks (about 5 months) for Cohort 3 and 20 weeks (about 5 months) for Cohort 4.

Start Date28 Aug 2024

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Danuglipron

100 Translational Medicine associated with Danuglipron

100 Patents (Medical) associated with Danuglipron

Literatures (Medical) associated with Danuglipron

01 Jan 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS

Article

Author: Deshmukh, Vaibhav ; Nandi, Sukhendu ; Jaiswal, Anupam ; Biradar, Rushikesh ; Deshpande, Rashmi

Small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists are emerging as promising therapeutic agents for type 2 diabetes mellitus (T2DM) and obesity. Danuglipron, a novel investigational GLP-1R agonist, has demonstrated notable efficacy in clinical trials. This study aimed to evaluate the in vitro metabolic stability of danuglipron and to identify its metabolites both in vitro and in vivo. Metabolite profiling was conducted using ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC-QToF-MS/MS). In vitro studies were performed in human liver microsomes (HLM), rat liver microsomes (RLM), and human S9 (HS9) fractions, while in vivo metabolites were identified from rat plasma, urine, and faeces. Seven novel phase I and phase II metabolites were characterized through high-resolution MS data, employing both data-dependent and data-independent acquisition, alongside in silico prediction tools. Key biotransformations included hydroxylation, O-dealkylation, oxetane ring hydrolysis followed by acetylation and methylation. The in vitro half-life (t₁/₂) of danuglipron was 208 ± 31 min in HLM and 81 ± 16 min in RLM, with corresponding intrinsic clearance (CL_int) values of 7.49 µL/min/mg and 35.57 µL/min/mg, respectively, indicating moderate hepatic metabolism and low clearance in both species. Molecular docking suggested that certain metabolites (M-1, M-2, M-7) may have stronger GLP-1R binding affinity than the parent compound, implying potential bioactivity. This comprehensive analysis offers valuable insights into danuglipron metabolic fate and supports further investigation of its metabolites in the treatment of T2DM and obesity.

26 Dec 2025·MEDICINE

Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis

Review

Author: Dahal, Krishna ; Bhattarai, Madhur ; Ahmed, Khalid ; Baral, Bidisha ; Shah, Sangam ; Parajuli, Sandesh Raman ; Paudel, Basanta Sharma ; Bhandari, Amit ; Khanal, Amit ; McDonald, Philip ; Bhattarai, Himal Bikram ; Basnet, Bibhusan ; Karki, Bibek ; Sah, Ranjit

Background::

Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules.

Methods::

We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark).

Results::

We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12 mg, 24 mg, 36 mg, and 45 mg, with nausea being the most common side effect in all groups. For the 45 mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90–6.71), while the 36 mg dose had an OR of 3.99 (95% CI: 2.22–7.18). The OR for the 24 mg dose was 5.66 (95% CI: 3.39–9.45), and the 12 mg dose showed an OR of 5.06 (95% CI: 3.31–7.73). Oral danuglipron at doses of 80 mg and 120 mg were also studied. The 120 mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30–8.34) while the 80 mg dose had an OR of 3.69 (95% CI: 1.77–7.67) indicating a significant decrease in gastrointestinal side effects.

Conclusion::

Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.

26 Aug 2025·CURRENT MEDICINAL CHEMISTRY

"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024)

Article

Author: Saliev, Alexandr Yu. ; Ivanov, Roman A. ; Salakhov, Tagir L. ; Tolkacheva, Elena V. ; Balakin, Konstantin V. ; Chernyshov, Vladimir V.

Background::

GLP-1 receptor peptide agonists have revolutionized type 2 di-abetes mellitus and obesity treatment, primarily through injection-based therapies. Small-molecule GLP-1 receptor agonists allow oral administration, but none are clini-cally established. Pfizer's danuglipron and lotiglipron, presented in 2018-2019, were "first-in-class" drug candidates, becoming prototypes for "next-in-class" drug develop-ment.

Objective::

This review summarizes "next-in-class" GLP-1 receptor agonists developed, identifying different relationships between the molecular structure and functional activi-ty of agonists.

Methods::

Patents containing danuglipron- and lotiglipron-like agonists from January 2021 to July 2024 were browsed in databases, such as Espacenet and Google Patents, using specified keywords. Over 5,000 compounds from 67 patent publications were an-alyzed.

Results::

Our analysis identified some key general SAR trends. The presence of a car-boxyl group leads to highly active agonists, but replacing it with bioisosteric analogs may improve the ADME profile of the target compounds. The introduction of specific privileged fragments, as well as the replacement of 1H-benzo[d]imidazole nucleus or (S)-oxetan-2-ylmethyl substituent in the prototype structure with bioisosteric heterocy-cles, may be viable approaches. The replacement of 1,4-disubstituted piperidine linked with its (S)-2-methyl-substituted homologue or O, N-disubstituted piperidin-4-ol may also result in highly potent agonists. Additionally, the classic 2,4-EWG-disubstituted benzyl alcohol residue allows significant variability.

Conclusion::

Despite the limited clinical success of danuglipron and lotiglipron, as well as the inherent problems associated with the complex nature of GLP-1R signaling, the current state of research and the abundance of novel, promising chemotypes of highly potent compounds suggest that approved GLP-1R agonists may emerge in the coming years.

103

News (Medical) associated with Danuglipron

23 Feb 2026

·www.fiercepharma.com

Obesity Power Rankings: Who will challenge Lilly and Novo?

None With the obesity market projected to exceed $130 billion by 2034, many major pharmaceutical players are rapidly advancing pipelines to capitalize on what is arguably the most dynamic space in the industry. To identify the companies positioned to outperform, FENIX has created the Obesity Power Rankings of the Top 10 players. For context, >20 companies were assessed across more than 15 weighted criteria, including pipeline depth, clinical differentiation, and commercial infrastructure, to derive a composite score out of five. If you’re interested in a deeper look at the full assessment framework, please contact the FENIX team. Below, FENIX outlines the rationale for all rankings and highlights key headwinds and tailwinds that shape each company’s position: Lilly (4.9/5): Lilly remains the undisputed market leader in obesity, as evidenced by its tirzepatide franchise becoming the world’s top-selling drug in 2025, surpassing Merck’s Keytruda to generate >$36 billion in annual revenue. While Lilly possesses a robust late-stage pipeline which is anticipated to help defend its leadership position, near-term momentum is expected to center on the orforglipron launch in Q2 2026. Considering Novo’s Wegovy Pill appears to hold a marginal edge in terms of efficacy, Lilly’s commercial team may need, for once, to come from behind. Novo Nordisk (4.8/5): Having effectively pioneered the modern obesity market with semaglutide, Novo entered 2026 confronting a convergence of executional challenges and a visible decline in innovation, factors that culminated in the company issuing its first negative annual sales outlook since semaglutide’s ascent. Novo now relies on strong launches of injectable 7.2mg Wegovy, Wegovy Pill, and CagriSema to stabilize its US market share and rebuild investor confidence. While these launches may alleviate near-term pressures, it remains uncertain whether Novo has truly identified a long-term successor to semaglutide. Pfizer (4.1/5): Following its $10 billion Metsera acquisition and licensing agreement with YaoPharma in 2025, Pfizer has significantly vaulted up the competitive rankings. While the company previously faced multiple setbacks in obesity (e.g., danuglipron and lotiglipron discontinuations), Pfizer finally appears to have assembled a differentiated pipeline that can fully leverage its established commercial and manufacturing infrastructure. Roche (4.0/5): Despite its historically limited presence in the cardiometabolic space, Roche has publicly emphasized its ambition to become a Top 3 player in the obesity market. Following the recent encouraging topline CT‑388 Phase 2 results, attention now turns to the upcoming Phase 2 petrelintide readout in H1 2026, a pivotal catalyst that will likely shape the trajectory of its partnership with Zealand and, ultimately, Roche’s broader obesity aspirations. AstraZeneca (3.6/5): A compelling case can be made that AZ has the pipeline depth to emerge as a dark horse contender for the third-place position in the power rankings. The company quietly advanced a broad mid-stage pipeline throughout 2025; and with multiple Phase 2 readouts expected in 2026, it's licensing agreement with CSPC Pharmaceuticals, which added a monthly dual agonist to its arsenal, further strengthens it as a serious contender. Amgen (3.3/5): Amgen is effectively placing a concentrated bet that MariTide’s extended dosing will be its key differentiator in the future obesity market. While quarterly maintenance dosing is differentiated, it remains to be seen whether the company can overcome the Phase 2 tolerability issues that unsettled investors at ADA 2025. Boehringer Ingelheim (3.0/5): With data from the Phase 3 survodutide program anticipated to begin reading out in H1 2026, BI is set to become the first challenger to the current Lilly+Novo duopoly. Even with positive Phase 3 survodutide data, BI likely needs to expand its pipeline beyond its Phase 2 triple agonist to become a long-term competitive player in the space. Regeneron (2.9/5): While it was previously believed Regeneron was taking a tangential approach in the obesity market, looking to develop lean mass-sparing assets, its in-licensing deal for olatorepatide in June 2025 revealed the company’s broader obesity ambitions. However, similar to both BI and Amgen, it is believed Regeneron also needs to further diversify its portfolio to be considered a future leader in obesity. Zealand Pharma (2.4/5): Zealand, guided by CEO Adam Steenburg’s ambition to end what he describes as the “Weight Loss Olympics,” is making a strategic bet that amylin will become the next foundational anti-obesity class. Following Zealand’s partnership with Roche for petrelintide, the upcoming Phase 2 ZUPREME-1 readout will offer the first meaningful look into whether petrelintide lives up to the TPP promise. Kailera Therapeutics (2.2/5): Having licensed China-based Hengrui’s GLP-1/GIP dual agonist (ribupatide), which has already demonstrated strong late-stage weight loss efficacy in a Chinese population, Kailera initiated its own Phase 3 program evaluating higher doses (>6 mg) over longer treatment durations. It will be interesting to see if Kailera follows the traditional path of partnering with Big Pharma or if it goes alone with a new US commercial model (i.e., solely direct-to-patient).

Phase 3Phase 2License out/in

19 Dec 2025

·www.pharmaceutical-technology.com

Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs

Eli Lilly’s oral GLP-1RA, orforglipron, has offered significant weight maintenance benefits during a Phase III study in obesity. Image credit: ChrisStock82 via Shutterstock.com. Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients transferred from injectable GLP-1RAs. During the 52-week Phase III ATTAIN-MAINTAIN study (NCT06584916), the weight loss pill offered significant weight maintenance benefits over placebo when used as an adjunctive therapy alongside a healthy diet and physical activity – meeting the trial’s primary endpoint. This impact was seen in patients who had previously received 72 weeks of treatment with the highest dose of either Lilly’s injectable weight loss drug, Zepbound (tirzepatide), or Novo Nordisk’s competitor GLP-1RA, Wegovy (semaglutide), who were enrolled from the SURMOUNT-5 head-to-head trial (NCT05822830). The average weight gain of patients transitioned from Wegovy to orforglipron was 0.9kg, while those transitioning from Zepbound to orforglipron experienced a 5kg weight gain after 52 weeks of maintenance therapy. The average weight of patients transitioned from Wegovy and Zepbound before the 52-week maintenance period was 95kg and 90.9kg, respectively, with the average weight after being 95.9kg in both cohorts. Orforglipron’s safety and tolerability profile also mirrored that seen in previous Phase III studies involving the drug, with the most common treatment-emergent adverse events (TEAEs) being mild-to-moderate and gastrointestinal in nature. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence TEAE-linked discontinuations were seen in 4.8% and 7.6% transitioning from Wegovy to orforglipron and placebo, respectively. Discontinuations were also observed in 7.2% and 6.3% of patients moving from Zepbound to orforglipron and placebo, respectively. Detailed results from this trial will be presented at an undisclosed future medical meeting. Obesity market competition intensifies Eli Lilly has submitted a new drug application (NDA) for orforglipron to the US Food and Drug Administration (FDA), which could see the therapy gain approval for obesity. In preparation for the drug’s potential market debut, Eli Lilly is investing heavily in its global manufacturing footprint for orforglipron. This includes new builds in Texas and Alabama , as well as a site expansion in Puerto Rico . Outside of the US, the company is also building a new Dutch manufacturing capacity dedicated to the manufacture of the GLP-1RA. However, it is not the only potential oral candidate on the emerging weight loss pill market, as Novo Nordisk’s Oral Wegovy (semaglutide) is currently under FDA review . GlobalData, parent company of Pharmaceutical Technology , currently forecasts that orforglipron will claim status as a mega-blockbuster seller in 2031, bringing in sales of $13bn during that year. Analysts expect the drug to launch in 2026. Meanwhile, a patient-based forecast predicts that oral Wegovy will reach sales of $4.4bn in 2031. Across the broader obesity market, GlobalData senior analyst Shehroz Mahmood noted that the ATTAIN-MAINTAIN results signal an emerging trend towards maintenance and switching protocols. Mahmood said: “With a growing pipeline of oral small molecules demonstrating promising efficacy and safety profiles, including recently Ascletis’ ASC30 and Structure Therapeutics’ aleniglipron, maintenance and switching studies could expand as companies seek differentiation in an increasingly crowded oral GLP-1RA landscape. “This emerging pattern suggests that the obesity space is pivoting toward comprehensive treatment flexibility as a key driver of long-term adherence and market share in chronic weight management.” Outside of the oral subcategory, Eli Lilly may have another leg up on rival Novo Nordisk, as its investigational glucose-dependent insulinotropic polypeptide (GIP), glucagon and GLP-1RA triple hormone agonist, retatrutide, recently triggered weight loss of up to 28.7% in the Phase III TRIUMPH-4 study. In the longer term, Eli Lilly and Novo Nordisk may face competition from a newly emerging player, Pfizer, which recently acquired obesity biotech Metsera through a highly publicised bidding war with Novo. Earlier this month, the company licensed an oral GLP-1RA asset from Fosun Pharma’s YaoPharma for $2bn, which could see Pfizer enter this lucrative market. This follows the discontinuation of its own weight loss pill, danuglipron , after a patient obtained a liver injury after receiving the therapy in a clinical trial. Pharmaceutical Technology Excellence Awards - Nominations Closed Nominations are now closed for the Pharmaceutical Technology Excellence Awards . A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact. Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing , Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines. Discover the Impact

Phase 3Clinical ResultAcquisitionNDA

09 Dec 2025

·firstwordpharma.com

Pfizer adds small molecule GLP-1 to pipeline via deal with Fosun unit

Pfizer will pay $150 million upfront for rights to a small-molecule GLP-1 receptor agonist being developed by Fosun Pharmaceutical's subsidiary, Yao Pharmaceutical. The deal includes development, regulatory and commercial milestones of up to $1.935 billion, as well as tiered sales royalties if the compound, known as YP05002, ultimately obtains approval."This investigational GLP-1 small molecule…complements and strengthens our growing portfolio of novel candidates for treating obesity and its adjacent diseases," remarked Chris Boshoff, Pfizer's president of R&D, in a release Tuesday.Earlier this year, Pfizer won a bidding war with Novo Nordisk for Metsera, finally agreeing to buy the biotech for up to $86.25 per share, or a total of about $10 billion. The acquisition is centred on Metsera's obesity programmes, including the ultra-long-acting GLP-1 agonist MET-097i and the monthly amylin analogue MET-233i, as well as two oral GLP-1 candidates.Pfizer's persistence in its pursuit of Metsera followed issues with its own weight-loss programmes, with the oral GLP-1 danuglipron scrapped earlier this year (for related analysis, read Vital Signs: Pfizer’s $10-billion question for Metsera).Combos on deckUnder the agreed terms, the companies said Yao Pharma will complete an ongoing Phase I study of YP05002 in Australia, with Pfizer being granted an exclusive license to further develop, manufacture and commercialise the therapy. Pfizer indicated that it plans to initiate combination studies of YP05002 with its GIPR antagonist PF-07976016, which is currently in Phase II development, and with other small molecules in its pipeline.

Phase 1License out/inAcquisitionPhase 2

100 Deals associated with Danuglipron

External Link

KEGG	Wiki	ATC	Drug Bank
D11910	-	-	DB16043

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	United States	Pfizer Inc.	06 Jan 2021
Diabetes Mellitus, Type 2	Phase 2	United States	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Bulgaria	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Canada	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Hungary	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Poland	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Slovakia	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	South Korea	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Taiwan Province	Pfizer Inc.	15 Oct 2019
Liver Injury	Phase 1	United States	Pfizer Inc.	30 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04889157 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	20	Placebo	jbkctqjfeq = mbsqkmlclh qmpzzdcnrn (xwvvptlovr, ltrfxtehyi - xzvekibxco) View more	-	01 Oct 2024
NCT04616027 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	42	PF-06882961 (Healthy and Normal Renal Function)	skoaplhypn(pmgwisvfuw) = cgmbtgfxdp mhsqgdzttd (jqgtedugft, 28) View more	-	10 May 2024
				PF-06882961 (T2DM Normal Renal Function)	skoaplhypn(pmgwisvfuw) = likqdpnsla mhsqgdzttd (jqgtedugft, 58) View more
NCT04604496 (CTgov)	Phase 1	Liver Injury	24	PF-06882961 (Without Hepatic Impairment)	sdiccxzydg(rwssfgwuso) = afiafavyne xemnixqucq (gkeyyynwbw, 50) View more	-	21 Mar 2024
				PF-06882961 (Mild Hepatic Impairment)	sdiccxzydg(rwssfgwuso) = tbvwauengk xemnixqucq (gkeyyynwbw, 33) View more
NCT04707313 (Corporate Publications) Manual	Phase 2	Obesity	-	Danuglipron	fwgwjqloyj(dgnjqaxhsc) = gedyiivngg rcxzuommha (eyipcdsska ) View more	Negative	01 Dec 2023
				Placebo	fwgwjqloyj(dgnjqaxhsc) = wtfdtndkkv rcxzuommha (eyipcdsska ) View more
NCT04621227 (CTgov)	Phase 1	Obesity	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	cvleagwjug(xhvocnsuyc) = lqhsltrkvb ucuchmnzkj (wzofeokekv, 43) View more	-	01 Dec 2023
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	cvleagwjug(xhvocnsuyc) = fyneylztnb ucuchmnzkj (wzofeokekv, 50) View more
NCT04617275 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	151	Placebo	laqfgmkoli(nzpnfgklxv) = yjtfxlxght tipqamldcr (ckyqnhqsrs ) View more	-	13 Jun 2023
				Danuglipron low starting dose (5-mg)	laqfgmkoli(nzpnfgklxv) = uouzvjuoxc tipqamldcr (ckyqnhqsrs ) View more
NCT03985293 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	uujnvjazus(rblfvuypfs) = zyqsjouxir cbolqtysct (ednciearsw, -0.70 to to 0.28) View more	Positive	22 May 2023
				Danuglipron 10 mg	uujnvjazus(rblfvuypfs) = quwwfrabic cbolqtysct (ednciearsw, -1.11 to to 0.72) View more
NCT03985293 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	hgzrvwxdms(zbxkwwpvnn) = mfljlqnahc jirdqixtdx (mnydfyvbma, -1.47 to -0.86) View more	Positive	22 May 2023
				Danuglipron 80 mg	zuxwqixsyv(vcorbcbcvq) = mmioptxpgo mksrlygaow (hkwjjzmvbk, -3.01 to -1.07)
NCT04617275 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Obesity	151	Placebo (Placebo (T2DM))	dwoscyaeof = qfofayzsul gbxqztjwzb (dtemiwapsw, rmacxbhivq - hmbxglqfme) View more	-	08 Dec 2022
				PF-06882961 (PF-06882961 80 mg BID Low, Slow (T2DM))	dwoscyaeof = mrecheepjr gbxqztjwzb (dtemiwapsw, yckjtjpaab - yoljiegnkk) View more
NCT04552470 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	37	danuglipron	wycveotlww(lctlliplcp) = Most treatment-emergent adverse events were of mild or moderate intensity. rufcmjsudu (yljurvnhln )	Positive	26 Nov 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis